Abeona Therapeutics Inc. (ABEO)
Company Description
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases.
Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa.
The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders.
In addition, it is developing AAV-based gene therapy through its AIM vector platform programs.
The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015.
Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
| Country | United States |
| IPO Date | Sep 19, 1980 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 136 |
| CEO | Dr. Vishwas Seshadri M.B.A., Ph.D. |
Contact Details
Address: 1330 Avenue of the Americas New York, New York United States | |
| Website | https://www.abeonatherapeutics.com |
Stock Details
| Ticker Symbol | ABEO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000318306 |
| CUSIP Number | 00289Y107 |
| ISIN Number | US00289Y2063 |
| Employer ID | 83-0221517 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Vishwas Seshadri M.B.A., Ph.D. | President, Chief Executive Officer & Director |
| Alison Hardgrove | Chief People Officer |
| Brian Kevany Ph.D. | Senior Vice President, Chief Technology Officer & CSO |
| Dr. Brendan M. O'Malley J.D., Ph.D. | Chief Legal Officer |
| Joseph Walter Vazzano CPA | Chief Financial Officer |
| Carl Denny | Senior Vice President of Regulatory Affairs |
| Dr. Madhav Vasanthavada M.B.A., Ph.D. | Senior Vice President, Chief Commercial Officer & Head of Business Development |
| Gregory Gin | Vice President of Investor Relations & Corporate Communications |
| Jon Voss | Vice President & Head of Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 20, 2025 | 8-K | Current Report |
| Mar 20, 2025 | 10-K | Annual Report |
| Mar 17, 2025 | 4 | Filing |
| Mar 04, 2025 | 4 | Filing |
| Feb 03, 2025 | 4 | Filing |
| Feb 03, 2025 | 4 | Filing |
| Feb 03, 2025 | 4 | Filing |
| Feb 03, 2025 | 4 | Filing |
| Feb 03, 2025 | 4 | Filing |
| Feb 03, 2025 | 4 | Filing |